Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Cardone

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 1, 2021
Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over timeSasha Thomson, Noah Witzke, Bishal Gyawali, et al.
Future Oncology (London, England)|February 14, 2018
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasisAlfonso Reginelli, Alfredo Clemente, Claudia Cardone, et al.
Oncotarget|November 16, 2017
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cellsStefania Napolitano, Giulia Martini, Erika Martinelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft ModelsTeresa Troiani, Stefania Napolitano, Giulia Martini, et al.
ESMO Open|April 2, 2020
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspectiveMatteo Lambertini, Angela Toss, Antonio Passaro, et al.
World Journal of Gastroenterology|September 9, 2016
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerVincenzo Sforza, Erika Martinelli, Fortunato Ciardiello, et al.
Cancers|June 23, 2019
Genomic Profiling of <i>KRAS/NRAS/BRAF/PIK3CA</i> Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR AgentsAnna Maria Rachiglio, Matilde Lambiase, Francesca Fenizia, et al.
Frontiers in Oncology|February 23, 2023
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case reportAlfonso De Stefano, Nicoletta Zanaletti, Antonino Cassata, et al.
World Journal of Gastroenterology|August 3, 2017
Present and future of metastatic colorectal cancer treatment: A review of new candidate targetsGiulia Martini, Teresa Troiani, Claudia Cardone, et al.
ESMO Open|February 2, 2018
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseErika Martinelli, Teresa Troiani, Vincenzo Sforza, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|May 1, 2021
Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over timeSasha Thomson, Noah Witzke, Bishal Gyawali, et al.
Future Oncology (London, England)|February 14, 2018
Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasisAlfonso Reginelli, Alfredo Clemente, Claudia Cardone, et al.
Oncotarget|November 16, 2017
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cellsStefania Napolitano, Giulia Martini, Erika Martinelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft ModelsTeresa Troiani, Stefania Napolitano, Giulia Martini, et al.
ESMO Open|April 2, 2020
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspectiveMatteo Lambertini, Angela Toss, Antonio Passaro, et al.
World Journal of Gastroenterology|September 9, 2016
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerVincenzo Sforza, Erika Martinelli, Fortunato Ciardiello, et al.
Cancers|June 23, 2019
Genomic Profiling of <i>KRAS/NRAS/BRAF/PIK3CA</i> Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR AgentsAnna Maria Rachiglio, Matilde Lambiase, Francesca Fenizia, et al.
Frontiers in Oncology|February 23, 2023
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case reportAlfonso De Stefano, Nicoletta Zanaletti, Antonino Cassata, et al.
World Journal of Gastroenterology|August 3, 2017
Present and future of metastatic colorectal cancer treatment: A review of new candidate targetsGiulia Martini, Teresa Troiani, Claudia Cardone, et al.
ESMO Open|February 2, 2018
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseErika Martinelli, Teresa Troiani, Vincenzo Sforza, et al.
Pageof 5